Page last updated: 2024-08-24

plerixafor and HIV Coinfection

plerixafor has been researched along with HIV Coinfection in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (12.82)	18.2507
2000's	19 (48.72)	29.6817
2010's	13 (33.33)	24.3611
2020's	2 (5.13)	2.80

Authors

Authors	Studies
Baba, M; Miyake, H; Okamoto, M; Takashima, K; Wang, X	1
Hamatake, M; Huang, W; Komano, J; Kumakura, S; Murakami, T; Okuma, K; Tanaka, R; Tanaka, Y; Toma, J; Yamamoto, N; Yamazaki, T; Yanaka, M	1
Ballweber, L; Fialkow, M; Hladik, F; Kreger, A; Lentz, G; McElrath, MJ; Robinson, B; Sakchalathorn, P; Terker, A	1
Boehringer, EM; Bogucki, DE; Bridger, GJ; Crawford, J; De Clercq, E; Hatse, S; Hernandez-Abad, PE; Metz, M; Nan, S; Princen, K; Schols, D; Skerlj, RT; Wang, Z; Wilson, T; Zhou, Y	1
Bachan, S; Fantini, J; Garg, H; Joshi, A; Mootoo, DR	1
Altieri, A; Belov, DS; Curreli, F; Debnath, AK; Kurkin, AV; Kwon, YD; Kwong, PD; Ramesh, RR	1
An, J; Ciechanover, A; Fang, X; Huang, LS; Huang, Z; Meng, Q; Schooley, RT; Xu, Y; Zhang, H; Zhang, X	1
Chen, H; Poznansky, MC; Tannous, BA; Wang, J	1
Arakelyan, A; Chernomordik, LV; Margolis, LB; Marin, M; Melikov, K; Melikyan, GB; Villasmil, R; Zaitsev, E; Zaitseva, E	1
Aquaro, S; De Luca, M; Garofalo, A; Grande, F; Ioele, G; Occhiuzzi, MA; Rizzuti, B; Svicher, V; Tucci, P	1
Cheng, YC; Drucker, N; Harrison, RES; Humphries, B; Lolis, EJ; Luker, GD; Luker, KE; Morikis, D; Murphy, JW; Rajasekaran, D; Rosenberg, EM; Shia, KS; Song, JS; Tsou, LK; Wang, CJ; Wu, CH	1
Bandera, A; Gori, A; Incontri, A; Perseghin, P; Pioltelli, PE; Verga, L	1
Alvarez, M; Badia, R; Ballana, E; Brander, C; Clotet, B; Crespo, M; Esté, JA; Gubern, A; Keppler, OT; Martí, R; Menéndez-Arias, L; Mothe, B; Pauls, E; Permanyer, M; Posas, F; Riveira-Muñoz, E; Ruiz, A; Torres-Torronteras, J	1
Biswas, P; Cozzi, P; García-Sastre, A; Ghezzi, S; Guzzo, C; Jabes, D; Lusso, P; Malnati, M; Martínez-Romero, C; Mongelli, N; Sironi, F	1
Liotta, DC; Mosley, CA; Skudlarek, JW; Wilson, LJ; Wiseman, JM	1
Bencini, A; Bianchi, A; Bulgheroni, E; Cabrera, C; Ferramosca, S; Galli, M; Lo Cicero, M; Martinez-Picado, J; Ruiz, L; Rusconi, S; Sirianni, F; Supuran, CT; Viganò, O	1
Anders, M; Bozek, K; Eckhardt, M; Kaiser, R; Kräusslich, HG; Lengauer, T; Müller, B; Sierra, S	1
Badia, R; Ballana, E; Clotet, B; Esté, JA; Pauls, E; Permanyer, M	1
Jacobson, O; Weiss, ID	1
Fujii, N; Lal, RB; Owen, SM; Rudolph, D; Schols, D; Yamamoto, N	1
Blauvelt, A; Borris, DL; Gulden, FO; Kawamura, T; Lederman, MM; McNamara, DT; Orenstein, JM; Sugaya, M; Zimmerman, PA	1
Maddon, PJ; Olson, WC	1
Boeser-Nunnink, B; Naarding, MA; Schols, D; Schuitemaker, H; Stalmeijer, EH; Van Rij, RP; Visser, JA	1
Alespeiti, G; Debnath, AK; He, Y; Zhao, Q	1
Badel, K; Bridger, GJ; Brown, S; Calandra, G; Collier, AC; Coombs, RW; Flexner, CW; Glesby, MJ; Hendrix, CW; Henson, GW; Jackson, JB; Lederman, MM; MacFarland, RT; Pollard, RB; Schols, D	1
Henderson, HI; Hope, TJ	1
Esté, JA; Telenti, A	1
Archibald, SJ; Greenman, J; Khan, A	1
Armand-Ugón, M; Clotet, B; Esté, JA; Moncunill, G; Pauls, E	1
Ayouba, A; Barré-Sinoussi, F; Cannou, C; Menu, E; Nugeyre, MT	1
Bridger, G; Fransen, S; Huang, W; Parkin, N; Petropoulos, CJ; Stawiski, E; Toma, J; Whitcomb, JM	1
Balzarini, J; Datema, R; De Clercq, E; De Vreese, K; Debyser, Z; Pauwels, R; Peichl, P; Rosenwirth, B; Witvrouw, M; Yamamoto, N	1
Datema, R; Hincenbergs, M; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Rosenwirth, B; Seifert, J; Warren, S	1
Blanco, J; Bridger, G; Cabrera, C; Clotet, B; De Clercq, E; Esté, JA; Gutierrez, A; Henson, G; Schols, D	1
Schols, D	1
De Clercq, E	1
Bordignon, PP; Brambilla, A; Clementi, M; Ghezzi, S; Lorini, AL; Menzo, S; Poli, G; Vicenzi, E	1
Bolognesi, DP; Galasso, G; Hammer, SM; Hirsch, MS; LaBranche, CC; Moore, JP	1

Reviews

8 review(s) available for plerixafor and HIV Coinfection

Article	Year
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacological research, 2020, Volume: 159 Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Benzylamines; Cyclams; Drug Contamination; HIV Infections; Humans; Neoplasms; Primary Immunodeficiency Diseases; Receptors, CXCR4; Signal Transduction; Tumor Microenvironment; Warts	2020
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy. Molecules (Basel, Switzerland), 2019, Feb-02, Volume: 24, Issue:3 Topics: Anti-HIV Agents; Benzylamines; CCR5 Receptor Antagonists; Cyclams; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Maraviroc; Pyridines; Receptors, CCR5; Receptors, CXCR4	2019
Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert opinion on therapeutic patents, 2009, Volume: 19, Issue:1 Topics: Animals; Anti-HIV Agents; Benzylamines; Cyclams; Drug Design; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Patents as Topic; Protein Binding; Receptors, CXCR4	2009
Resistance to HIV-1 entry inhibitors. Current drug targets. Infectious disorders, 2003, Volume: 3, Issue:4 Topics: Amides; Anti-HIV Agents; Benzylamines; CD4 Immunoadhesins; Cyclams; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Peptide Fragments; Piperazines; Quaternary Ammonium Compounds	2003
HIV entry inhibitors. Lancet (London, England), 2007, Jul-07, Volume: 370, Issue:9581 Topics: Anti-HIV Agents; Benzylamines; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclams; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Peptide Fragments; Virus Replication	2007
Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Current medicinal chemistry, 2007, Volume: 14, Issue:21 Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Chemokines; Cyclams; Heterocyclic Compounds; HIV Infections; Humans; Neoplasms; Receptors, CXCR4; Structure-Activity Relationship	2007
Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Molecular pharmacology, 2000, Volume: 57, Issue:5 Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Chemokines, CXC; Cyclams; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Receptors, CXCR4; Structure-Activity Relationship	2000
HIV fusion and its inhibition. Antiviral research, 2001, Volume: 50, Issue:2 Topics: Anti-HIV Agents; Benzylamines; CD4 Immunoadhesins; Cyclams; Enfuvirtide; Heterocyclic Compounds; HIV; HIV Envelope Protein gp41; HIV Infections; Humans; Membrane Fusion; Peptide Fragments; Receptors, HIV	2001

Trials

2 trial(s) available for plerixafor and HIV Coinfection

Article	Year
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of acquired immune deficiency syndromes (1999), 2004, Oct-01, Volume: 37, Issue:2 Topics: Anti-HIV Agents; Benzylamines; Cyclams; Drug Administration Schedule; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Receptors, CXCR4; Treatment Outcome	2004
Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Genetic Variation; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Envelope Protein gp160; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Peptide Fragments; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies	2008

Article

Year

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

Journal of acquired immune deficiency syndromes (1999), 2004, Oct-01, Volume: 37, Issue:2

Topics: Anti-HIV Agents; Benzylamines; Cyclams; Drug Administration Schedule; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Receptors, CXCR4; Treatment Outcome

2004

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7

Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Genetic Variation; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Envelope Protein gp160; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Peptide Fragments; Phylogeny; Receptors, CCR5; Receptors, CXCR4; Retrospective Studies

2008

Other Studies

29 other study(ies) available for plerixafor and HIV Coinfection

Article	Year
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Imidazoles; Leukocytes, Mononuclear; Molecular Sequence Data; Sulfoxides; Virus Replication	2007
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Animals; Anti-HIV Agents; Calcium Signaling; Cell Line; Cells, Cultured; Chemokine CXCL12; CHO Cells; Cricetinae; Cricetulus; Fluorescent Antibody Technique; HIV Infections; HIV-1; Humans; Mice; Mice, SCID; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, CXCR4	2009
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2 Topics: Adult; Anti-HIV Agents; Benzothiepins; Cells, Cultured; Enfuvirtide; Female; Flow Cytometry; Genotype; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; In Vitro Techniques; Microscopy, Confocal; Peptide Fragments; Polymerase Chain Reaction; Virus Integration	2010
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Anti-HIV Agents; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Models, Chemical; Molecular Structure; Pyridines; Receptors, CXCR4; Structure-Activity Relationship; T-Lymphocytes; Virus Replication	2010
Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides. Bioorganic & medicinal chemistry, 2011, Aug-15, Volume: 19, Issue:16 Topics: Antiviral Agents; Cell Line; Disaccharides; Drug Evaluation, Preclinical; Esters; Fatty Acids; Galactosylceramides; Glycolipids; HIV; HIV Envelope Protein gp120; HIV Infections; Humans; Micelles; Peptides; Protein Binding; Receptors, CXCR4; Structure-Activity Relationship; Surface Properties	2011
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Anti-HIV Agents; Biomimetic Materials; CD4 Antigens; Cell Line; Crystallography, X-Ray; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Docking Simulation; Molecular Targeted Therapy; Pyrroles; Structure-Activity Relationship; Thiazoles; Virus Internalization	2017
A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist. European journal of medicinal chemistry, 2022, Mar-05, Volume: 231 Topics: Binding, Competitive; Chemokine CXCL12; HIV Infections; Humans; Models, Molecular; Receptors, CXCR4; Signal Transduction	2022
Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine. Cell host & microbe, 2017, Jul-12, Volume: 22, Issue:1 Topics: Amides; Anoctamins; Antibodies, Monoclonal; Benzylamines; Calcium; CD4 Antigens; Cell Line; Cell Membrane; Cyclams; HEK293 Cells; HeLa Cells; Heterocyclic Compounds; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Membrane Fusion; Phosphatidylserines; Phospholipid Transfer Proteins; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Signal Transduction; Viral Envelope Proteins; Virus Activation; Virus Attachment; Virus Internalization; Virus Replication	2017
Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant. Cell chemical biology, 2019, 05-16, Volume: 26, Issue:5 Topics: Benzylamines; beta-Arrestin 2; Chemokine CXCL12; Cyclams; HEK293 Cells; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Protein Conformation, alpha-Helical; Protein Structure, Tertiary; Receptors, CXCR4; Signal Transduction; Small Molecule Libraries	2019
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies. AIDS (London, England), 2013, Mar-27, Volume: 27, Issue:6 Topics: Benzylamines; Cyclams; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; HIV Infections; Humans; Male; Middle Aged; Receptors, CXCR4; Treatment Outcome	2013
Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. Journal of immunology (Baltimore, Md. : 1950), 2014, Aug-15, Volume: 193, Issue:4 Topics: Benzylamines; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Cycle Checkpoints; Cells, Cultured; Cyclams; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 6; HEK293 Cells; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Lymphocytes; Macrophages; Monomeric GTP-Binding Proteins; Myeloid Cells; Phosphorylation; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; SAM Domain and HD Domain-Containing Protein 1	2014
Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains. Journal of translational medicine, 2015, Apr-02, Volume: 13 Topics: 3T3 Cells; Animals; Antiviral Agents; Benzylamines; Cell Death; Cell Line; Cyclams; Cyclohexanes; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Membrane Fusion; Mice; Receptors, CCR5; Receptors, CXCR4; Triazoles; Virus Internalization; Virus Replication	2015
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. Molecules (Basel, Switzerland), 2009, May-22, Volume: 14, Issue:5 Topics: Amines; Anti-HIV Agents; Benzylamines; Cyclams; Drug Resistance, Multiple; Drug Resistance, Viral; Heterocyclic Compounds; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Molecular Structure; Phenotype; Polyamines; Receptors, CXCR4	2009
An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data. Retrovirology, 2012, Jul-25, Volume: 9 Topics: Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Computational Biology; Cyclams; Cyclohexanes; Genetic Vectors; HEK293 Cells; Heterocyclic Compounds; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Models, Biological; Molecular Sequence Data; Multivariate Analysis; Phenotype; Receptors, CCR5; Receptors, CXCR4; Transfection; Triazoles; Virus Internalization	2012
Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells. The Journal of biological chemistry, 2012, Sep-14, Volume: 287, Issue:38 Topics: Anti-HIV Agents; Antibodies, Monoclonal; Benzylamines; CD4-Positive T-Lymphocytes; Coculture Techniques; Cyclams; Dose-Response Relationship, Drug; Endocytosis; Endosomes; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Virus Internalization; Virus Replication	2012
CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy. Theranostics, 2013, Volume: 3, Issue:1 Topics: Animals; Benzylamines; Cyclams; Diagnostic Imaging; Heterocyclic Compounds; HIV Infections; Humans; Mice; Neoplasms; Receptors, CXCR4	2013
Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds. Journal of medical virology, 2002, Volume: 68, Issue:2 Topics: Anti-HIV Agents; Benzylamines; Cell Line; Cohort Studies; Cyclams; Drug Resistance, Viral; Heterocyclic Compounds; HIV Infections; HIV-1; HIV-2; Humans; In Vitro Techniques; Longitudinal Studies; Receptors, CCR5; Receptors, CXCR4	2002
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 2003, Jul-08, Volume: 100, Issue:14 Topics: Antibodies, Monoclonal; Benzylamines; CCR5 Receptor Antagonists; CD4 Antigens; CD4-Positive T-Lymphocytes; Cell Adhesion Molecules; Chemokine CCL5; Cyclams; Dendritic Cells; Endocytosis; Epithelial Cells; Female; Genetic Predisposition to Disease; Genotype; Heterocyclic Compounds; HIV; HIV Infections; Humans; Langerhans Cells; Lectins, C-Type; Male; Open Reading Frames; Polymorphism, Genetic; Receptors, CCR5; Receptors, Cell Surface; Receptors, CXCR4; Sequence Deletion; Virus Replication	2003
In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. Journal of virology, 2004, Volume: 78, Issue:6 Topics: Anti-HIV Agents; Antibodies, Monoclonal; Antimicrobial Cationic Peptides; Benzylamines; Cell Line; Cyclams; Evolution, Molecular; Genetic Variation; Heterocyclic Compounds; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Receptors, CXCR4	2004
A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology, 2004, Sep-01, Volume: 326, Issue:2 Topics: Amides; Animals; Anti-HIV Agents; Benzylamines; CCR5 Receptor Antagonists; CD4 Antigens; Cell Line; Cyclams; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Protein Conformation; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Virulence; Virus Replication	2004
The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection. Virology journal, 2006, May-25, Volume: 3 Topics: Benzylamines; beta-Galactosidase; Binding Sites; CD4 Immunoadhesins; Cell Fusion; Cell Line, Tumor; Cold Temperature; Cyclams; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Membrane Fusion; Peptide Fragments; Receptors, CCR5; Receptors, CXCR4; Time Factors	2006
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1 Topics: Amides; Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Cyclams; Evolution, Molecular; Genetic Variation; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Peptide Fragments; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Sequence Alignment; Time Factors; Virus Attachment	2008
Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro. Retrovirology, 2008, Mar-31, Volume: 5 Topics: Benzylamines; CCR5 Receptor Antagonists; CD4-Positive T-Lymphocytes; Cell Communication; Cell Line; Cells, Cultured; Coculture Techniques; Cyclams; Enfuvirtide; Female; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Models, Biological; Niacinamide; Peptide Fragments; Piperazines; Placenta; Receptors, CXCR4; Trophoblasts; Virus Replication	2008
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:4 Topics: Animals; Antiviral Agents; Benzylamines; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclams; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Heterocyclic Compounds; HIV Infections; HIV-1; HIV-2; Humans; Monocytes; Rabbits; Structure-Activity Relationship	1994
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:3 Topics: Animals; Antiviral Agents; Benzylamines; CD4-CD8 Ratio; Chromatography, High Pressure Liquid; Cyclams; Didanosine; Drug Implants; Heterocyclic Compounds; HIV Infections; HIV-1; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, SCID; Rats; Spectrophotometry, Ultraviolet; Virus Replication; Zidovudine	1996
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Journal of virology, 1999, Volume: 73, Issue:7 Topics: Adaptation, Biological; Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Genotype; Giant Cells; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Peptide Fragments; Phenotype; Receptors, CCR5; Receptors, CXCR4; Virus Replication	1999
Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1999, Volume: 61, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Benzylamines; Cyclams; Heterocyclic Compounds; HIV; HIV Infections; Humans; Receptors, CXCR4; T-Lymphocytes	1999
AMD 3100. JM 3100, SDZ SID 791. Drugs in R&D, 1999, Volume: 2, Issue:5 Topics: Animals; Anti-HIV Agents; Benzylamines; Clinical Trials, Phase II as Topic; Cyclams; Drugs, Investigational; Heterocyclic Compounds; HIV Infections; HIV-1; HIV-2; Humans; Injections, Subcutaneous; Mice; Mice, SCID; Molecular Weight; Protein Binding; Rats	1999
Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands. Virology, 2001, Feb-15, Volume: 280, Issue:2 Topics: Amino Acid Sequence; Base Sequence; Benzylamines; CCR5 Receptor Antagonists; Cell Membrane; Cells, Cultured; Chemokine CCL5; Cyclams; DNA, Viral; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Ligands; Molecular Sequence Data; Receptors, CCR5; Receptors, CXCR4; Virus Replication	2001